Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Guerbet (France) sales up as contrast agent phased out

This article was originally published in Clinica

Executive Summary

Guerbet (France) has decided to drop its Telebrix 38 contrast agent and recall stocks in France and abroad over the next few months. The product withdrawal follows several reports to the Agence du Medicament of product crystallisation. The agency asked for some batches to be removed, but Guerbet has withdrawn the product as "a cautious move", Philippe Barthelet, Guerbet's financial director, told Clinica. He says no instances of clinical problems have been reported.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT090057

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel